GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Cash Conversion Cycle

AtriCure (AtriCure) Cash Conversion Cycle

: 177.51 (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

AtriCure's Days Sales Outstanding for the three months ended in Dec. 2023 was 44.55.
AtriCure's Days Inventory for the three months ended in Dec. 2023 was 221.55.
AtriCure's Days Payable for the three months ended in Dec. 2023 was 88.59.
Therefore, AtriCure's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 177.51.


AtriCure Cash Conversion Cycle Historical Data

The historical data trend for AtriCure's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.46 162.47 151.07 142.11 166.39

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.37 141.15 151.57 175.37 177.51

Competitive Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure Cash Conversion Cycle Distribution

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where AtriCure's Cash Conversion Cycle falls into.



AtriCure Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

AtriCure's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=43.51+210.1-87.22
=166.39

AtriCure's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=44.55+221.55-88.59
=177.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure  (NAS:ATRC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


AtriCure Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of AtriCure's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director